Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 09:00 ET | Source: HCW Biologics Inc.

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

Watch the "What This Means" video here Featuring the Company’s pembrolizumab-based immune checkpoint inhibitor MIRAMAR, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”...
September 16, 2025 08:00 ET | Source: HCW Biologics Inc.

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in...
August 25, 2025 08:00 ET | Source: HCW Biologics Inc.

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market.